Pharmaceutical Services Monitor – Trends and Future Outlook
The ongoing drug development bonanza heads into another bullish year…
The biopharmaceutical industry has experienced unprecedented advances over the past decade. Why? Beyond the science, novel service models have facilitated more efficient and cost-effective drug development, with the advent of outsourcing as a key strategy—which continues to proliferate. Record investment in drug development companies and a desire to access best-in-class talent and technology continues to fuel this growth and drive its own brand of innovation—from cutting-edge capabilities and tools to tech-enabled services and eClinical companies. Together, these changes allow today’s biotech and pharmaceutical companies to better optimize drug discovery, clinical results, and market success, evidenced through the discovery of new therapies, accelerated time to market, improved patient outcomes, and, ultimately, increased return on capital and equity appreciation. At Edgemont, we help pharmaceutical services companies expand even further on their success. We’ve been a leading advisor to these businesses since the industry’s early days. And with unsurpassed expertise across the full spectrum of service, software, and technology companies, we can help secure better transaction outcomes for our clients—so they can continue to develop life-changing therapeutics.
Edgemont has been an exceptional partner and key element to our success. Their strategic insights, industry knowledge, and transaction execution expertise proved invaluable to ERG’s formation, growth, and value creation, and in supporting us to build an industry-leading model for clinical research site services to facilitate improved drug development services for our biopharmaceutical and CRO clients. Edgemont’s M&A expertise in pharmaceutical services and the clinical research site services market in particular is beyond compare, and their commitment to ERG and our success exceeded our expectations.
We selected Edgemont as our advisor based on their unparalleled M&A expertise in the clinical research services industry and extensive experience advising companies focused on CNS drug development services. Their industry knowledge and transaction expertise were an ideal fit with our strategic needs. They proved to be a trusted and immensely valuable advisor. Their efforts resulted in a highly successful transaction with an exceptional partner for our company in Bioclinica.
We chose to work with Edgemont after interviewing several firms. We found their level of transaction expertise and knowledge of pharmaceutical research services to be a perfect match for our advisory needs. We really appreciate the level of commitment the Edgemont team showed to our engagement and Edgemont’s work resulted in a great transaction for Miami Research Associates.
Cell and gene therapies are still in their infancy, but have enormous potential…